Abstract: Neonatal diabetes mellitus (DM) is defined by the onset of persistent hyperglycemia within the first six months of life but may present up to 12 months of life. A gene mutation affecting pancreatic beta cells or synthesis/secretion of insulin is present in more than 80% of the children with neonatal diabetes. Neonatal DM can be transient, permanent, or be a component of a syndrome. Genetic testing is important as a specific genetic mutation can significantly alter the treatment and outcome. Patients with mutations of either KCNJ11 or ABCC8 that encode subunits of the K ATP channel gene mutation can be managed with sulfonylurea oral therapy while patients with other genetic mutations require insulin treatment.
Introduction
Neonatal diabetes mellitus (DM) is defined by the onset of persistent hyperglycemia within the first six months of life. It is often caused by a mutation in a single gene affecting development and function of pancreatic beta cells leading to diminished insulin secretion/function. While most patients with neonatal DM present within the first 6 months of life, some may present up to 12 months of life. [1] [2] [3] [4] [5] In contrast, it is unusual for autoimmune type 1 diabetes to present within the first six months of life.
5,6
Epidemiology Incidence of neonatal DM is thought to range from 1:90,000 to 1:160,000 live births. 7, 8 Hyperglycemia in a neonate is not an uncommon occurrence. 9 Therefore, making the diagnosis of neonatal DM can be difficult. Neonatal hyperglycemia is more common to develop in the firs 3-5 days of life and resolve within 2-3 days of onset but can persist up to 10 days. The difficulty in diagnosis is especially true in the preterm population or low birth weight infants. 2, 10 The prevalence of hyperglycemia in preterm infants can vary from 25% to 75%. [9] [10] [11] Common reasons for hyperglycemia in these patients include: sepsis, increased counter-regulatory hormones due to stress, parenteral glucose administration and medications such as steroids and beta-adrenergic agents. Also in critically ill preterm neonates, there is evidence that shows this population has some degree of pancreatic insulin secretion insufficiency and relative insulin resistance. 9 However, in a study of 750 patients with diabetes diagnosed before 6 months of age (146 preterm patients born <37 weeks and 604 born ≥37 weeks), a genetic etiology was found in 97/146 (66%) preterm infants compared with 501/604 (83%) born ≥37weeks. A genetic etiology was noted less frequently in early preterm infants (<32 weeks, 31%) than those born between 32-<37 weeks (81%) and ≥37 weeks of gestation (83%). There was no difference in the age at presentation between preterm and term infants (1 week vs 0.7 weeks). 10 The diagnosis of neonatal DM, therefore, should be considered in the presence of insulin-dependent hyperglycemia without an alternative causative factor in both preterm infants and in term infants.
Pathogenesis
A genetic mutation is found in approximately 80% of children with neonatal diabetes. 1, 3 The number of genes that are found in children with neonatal diabetes continues to increase and there are more than 20 known genetic causes for neonatal DM. 1, 2, 12, 13 The various genes are associated with specific inheritance pattern, phenotype, and clinical features. 2, 3, 5, 13 The genes associated with neonatal diabetes play a vital role in the development of pancreatic beta cells and synthesis and secretion of insulin. In a large series of 1020 patients diagnosed with neonatal DM before 6 months of age, causal mutations were found in 82% of the cases after comprehensive genetic testing including Sanger sequencing, 6q24 methylation analysis, and targeted next-generation sequencing of all known neonatal diabetes genes.
1 Mutations in the potassium channel genes (KCNJ11 and ABCC8) were the most common cause (38.2%) of neonatal diabetes but were identified less frequently in consanguineous families (12% in consanguineous families vs 46% in non-consanguineous families).
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Mutations in the INS gene that encodes insulin were found in 10% of patients from non-consanguineous and consanguineous families. A homozygous mutation in EIF2AK3 gene was the most common genetic cause in consanguineous families (Wolcott-Rallison syndrome, 24%). 1 The underlying mechanisms for the various gene mutations that lead to development of neonatal diabetes can be classified into three categories:
1. Alteration in beta cell function affecting synthesis or secretion of insulin -KCNJ11, ABCC8, GCK, INS, RFX6, SLC2A2, SLC19A2 2. Pancreatic hypoplasia or aplasia -PDX1 (IPF1),  PTF1A, HNF1B, MNX1, RFX6, GATA4, GATA6,  GLIS3, NKX2-2, NEUROG3, NEUROD1, PAX6  3. Damage to pancreatic beta cells -INS, EIF2AK3, IER3IPI, FOXP3, WFS1
Presentation
The clinical presentation varies from incidentally detected asymptomatic hyperglycemia to severe dehydration and diabetic ketoacidosis (DKA). 5, 14 Common clinical manifestations include being small for gestational age due to prenatal intrauterine growth restriction from deficiency of functional insulin which is important for in-utero growth. Extra-pancreatic findings sometimes associated with neonatal DM are usually helpful clues toward presence of underlying genetic mutation. [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] • Extra-pancreatic findings that can be associated with a specific genetic mutation are: Overexpression of genes on the 6q24 locus is the most common cause of transient neonatal diabetes. This is a consequence of loss of imprinting at 6q24 by uniparental disomy, by duplication of this region (paternal duplication), or by loss of DNA methylation, and thus activation of the maternal allele. 2, 26, 27 This region includes the genes ZAC and HYMAI. ZAC is a C2H2 zinc-finger transcription factor with multiple functions, including acting as a coactivator with p53 of Apaf1 (apoptotic protease activating factor 1) transcription, regulating the histone acetyltransferase activity of p300, and serving as a coactivator or corepressor of several nuclear hormone receptors. 28 HYMAI is an untranslated RNA of undetermined function. 26 Patients with 6q24 mutation usually present earlier than those with KCNJ11/ABCC8 mutation. 5 Additional features that may present in children with 6q24-related neonatal DM are macroglossia or umbilical hernia. Treatment for patients with 6q24-related neonatal diabetes in the early phase is insulin therapy. However, in older patients, non-insulin therapies such as those used for type 2 diabetes may be effective. As high as 14% of patients in a case series of 6q24-related transient neonatal DM developed hypoglycemia after remission of diabetes. 29 The second most common cause of transient neonatal DM is mutations in the two genes encoding the subunits of the voltage-dependent potassium channels. 
Permanent Neonatal DM
The most common cause of permanent neonatal diabetes is activating heterozygous mutations in KCNJ11 or ABCC8. These mutations account for more than 50% of all cases of 5 and most patients present before 6 months of age, though presentation after 6 months of age has been reported. As K ATP channels are expressed in the brain, patients with KCNJ11 mutations may have a wide range of neurocognitive disabilities such as decreased ability for reasoning, reading, vocabulary, and auditory working memory compared with sibling controls. 31, 32 Patients may also demonstrate signs and symptoms of sleep disturbance, attention deficit hyperactivity disorder as well as delays in learning, social-emotional, and behavioral development. 33 Severe cases of KCNJ11 mutation may have developmental delay and epilepsy, referred to as the DEND syndrome (Developmental delay, Epilepsy, and Neonatal Diabetes). Effects can vary from mild delays to severe delays with seizures. Patients with mutations in these two genes are sensitive to sulfonylurea (SU) treatment.
The second most common form of permanent neonatal diabetes after KCNJ11/ABCC8 gene mutation is mutationin the insulin gene (INS). Mutations in the INS can be present in up to 20% of infants with permanent neonatal DM. 1, 34 Mutation in this gene results in misfolding of the insulin protein which results in increased endoplasmic reticulum stress and eventual beta-cell death. The median age for diagnosis is at 10 weeks and 30% of these patients will present with DKA. 5 In a study of patients with permanent neonatal diabetes, those with mutations in the INS were diagnosed later than ATP-sensitive K(+) channel mutation carriers (11 vs 8 weeks). 34 Patients do not have any other phenotypic features other than permanent neonatal diabetes and require lifelong treatment with insulin. 35 
Syndromic Forms of Neonatal DM
There are several syndromes that are associated with neonatal DM. The mechanisms leading to presence of neonatal DM in various syndromes include beta-cell destruction, pancreatic hypoplasia or aplasia, impaired beta-cell function or severe insulin resistance. The most common syndrome is Wolcott-Rallison syndrome which is an autosomal recessive disorder caused by a mutation in EIF2A, a gene encoding the translation initiation factor 2-alpha kinase 3 important in regulation of the endoplasmic reticulum. 17 Other features are hepatic dysfunction and skeletal dysplasia. It occurs in about 30% of cases with consanguineous families.
A few of the syndromic forms are more common in consanguineous families, these include EIF23, GCK, GLIS3, RFX6, IER3IP1, and MNX1. 2 Other more rare syndromes that present with neonatal DM include IPEX syndrome (X-linked disorder that has immune dysregulation, polyendocrinopathy, and enteropathy -mutation in FOXP3), Fanconi Bickel syndrome (autosomal recessive disorder that has liver dysfunction and hypergalactosemia -mutation of SLC2A2), Rogers syndrome (autosomal recessive disorder that has thiamine-responsive megaloblastic anemia and sensorineural hearing loss -mutation of SLC19A2), Wolfram syndrome (autosomal recessive disorder that has diabetes insipidus, optic atrophy, and deafness -mutation of WFS1), and RabsonMendenhall syndrome (post-prandial hyperglycemia, fasting hypoglycemia, poor linear growth, and impaired muscle and adipose development -mutation of INSR).
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Differential Diagnosis
Neonatal diabetes needs to be distinguished from autoimmune type 1 diabetes. Most patients diagnosed with diabetes after 6 months of age, and especially after 12 months of age will have autoimmune type 1 diabetes. 6 In a study of children with diabetes onset before 13 months of age, the median age for diagnosis for infants with type 1 diabetes was 42.6 weeks (IQR 37.4-50.4) and 87.5% presented in DKA. 5 Most of these patients will test positive for at least one of the specific diabetes-related autoantibodies.
Diagnostic Workup
The first approach to hyperglycemia is evaluating if a specific cause could be the contributing factor. This should include assessing the amount of glucose administration. Ideal glucose infusion rates should be 6 to 12 mg/ kg/min in a neonate for effective growth and nutrition.
as pancreatic hypoplasia or agenesis is associated with certain genetic mutations. Neonatal blood contains a high proportion of fetal hemoglobin (HbF), whereas hemoglobin A (HbA) accounts for only 10-20%. During the first 6 months of life, HbF is gradually replaced by HbA. Therefore, HbA1c is less suitable to diagnose diabetes mellitus in infants <6 months of age. Measurement of diabetes-related autoantibodies (glutamic acid decarboxylase, islet cell, insulin, zinc transporter, and tyrosine phosphatases) is helpful in infants between 6 months and 12 months of age. Most children with type 1 diabetes will be positive for at least one autoantibody.
Genetic Testing
Genetic testing should be strongly considered for infants who have persistent hyperglycemia as prognosis and treatment options for monogenic forms of neonatal DM are influenced to a major extent by the specific gene that is mutated. Most patients with mutations in KCNJ11 and ABCC8 are responsive to sulfonylurea therapy and can be transitioned from insulin to sulfonylurea therapy after the genetic basis for their diabetes has been identified. In a large international cohort study with clinically diagnosed diabetes before 6 months of age, 80% had a known genetic diagnosis. 1,2 Term infants and premature infants born at more than 32 weeks gestation are more likely to have a monogenic cause. However, Besser et al showed that 31% of all preterm infants with diabetes born at less than 32 weeks gestation were also diagnosed with monogenic cause, suggesting that genetic testing should also be performed in preterm infants. 10 Chromosome 6q24 imprinting abnormalities (27% vs 12%) and GATA6 mutations (9% vs 2%) occurred more commonly in preterm than term infants while mutations in KCNJ11 were less common (21% vs 34%). Within their study, they showed that 37% of premature infants have potassium channel mutation and therefore timely genetic testing referral can improve control by replacing insulin with sulfonylurea therapy. 10 Targeted gene panels are available in various laboratories for genes associated with neonatal diabetes. Early comprehensive testing has led to a change in the management of patients with neonatal diabetes. The use of exome and genome sequencing has resulted in the identification of 2 novel disease genes (GATA6 and STAT3) and a novel regulatory element of PTF1A, in which mutations cause pancreatic agenesis. 12 Genetic testing is recommended for all cases of diabetes diagnosed less than 12 months of age. 2 Latest expert guidelines recommend that all patients diagnosed with diabetes in the first 6 months of life should have immediate molecular genetic testing to define their subtype of monogenic neonatal diabetes mellitus (NDM), as type 1 diabetes is extremely rare in this subgroup. In patients diagnosed between 6 and 12 months of age, testing for NDM is recommended in those without islet antibodies as the majority of patients in this age group have type 1 diabetes. 13 Median duration of diabetes at the time of genetic testing was noted to decrease from more than 4 years before 2005 to less than 3 months after 2012. 1 
Treatment
The initial management in a neonate with persistent hyperglycemia is reduction in the glucose infusion rate to physiologic glucose requirements for optimum growth and nutrition (6-12 mg/kg/min). Additionally, underlying conditions such as sepsis need to be treated. An attempt should be made, if medically safe, to decrease the dose of or discontinue medications that can result in hyperglycemia such as epinephrine, norepinephrine, dopamine or glucocorticoids.
If the infant has dehydration, electrolyte imbalance or ketoacidosis, intravenous fluids and electrolytes should be administered with close monitoring of fluid status and electrolytes. All infants with persistent hyperglycemia should initially be started on an intravenous insulin infusion. Some studies showed effective glucose control with insulin rates ranging as low as 0.02 units/kg/hr. 36 Other studies in very low birth weight infants often used an initial dose of 0.05 units/kg/hr. 9, 36 Blood glucose levels need to be monitored closely when on insulin infusion, ideally every hour. Insulin infusion rates should be adjusted in small increments of 0.01 units/kg/hr when glucose levels are less than 100 or greater than 200 mg/dL. Patients should be transitioned to subcutaneous insulin therapy if hyperglycemia persists after oral feedings have been established. Subcutaneous insulin therapy can be delivered via multiple daily injections or as a continuous subcutaneous insulin infusion (CSII). The initial dose via either of these delivery mechanisms should be conservative to decrease the risk of hypoglycemia. Subcutaneous insulin should be given when blood glucose values are at least above 200-250 mg/dL.
When using the multiple daily injections regimen, rapidacting insulin analogs such as insulin aspart, insulin lispro or glulisine are recommended 3-4 times per day before a feed. 37 The starting dose recommended for these rapid-acting insulin is 0.1 to 0.15 units/kg/dose if the preprandial glucose is above 200-250 mg/dL. It is recommended that all preprandial Continuous subcutaneous insulin infusion (CSII) via an insulin pump offers the advantage of the ability to deliver smaller doses of insulin relative to the multiple daily injections regimen. 38, [40] [41] [42] [43] Some infants may still need dilution of insulin for the insulin pump. The initial dose of basal insulin using the CSII is 0.1 to 0.3 units/kg/day. This can be adjusted to maintain blood glucose values between 100 and 200 mg/dL. Correction doses should be given if preprandial blood glucose values are above 250 mg/dL. The minimum basal rates for insulin pumps range between 0.025 and 0.05 units/hr. 2 
Sulfonylurea Therapy
Sulfonylurea therapy is effective in treatment of hyperglycemia in patients with neonatal DM who have a mutation in the KCNJ11 and ABCC8 genes. Up to 90-95% of patients with neonatal DM caused by these mutations are able to be taken off of insulin therapy after initiation of SU therapy. 2, 44 Sulfonylureas (SU) act on the K ATP channel to promote closure, allowing for insulin to be released from the beta cells. Glyburide (Glibenclamide) is the SU drug that has been used in a majority of patients with neonatal diabetes. [44] [45] [46] [47] [48] [49] [50] Other sulphonylureas such as glipizide, gliclazide, tolbutamide, and glimepiride have been used rarely but do not offer an advantage over glyburide. 44, 45 Since SU therapy increases insulin release, there is a risk for hypoglycemia to occur, especially if an infant or child has decreased oral intake. However, the risk for hypoglycemia with SU therapy is decreased in comparison to insulin therapy. In a 10-year multicenter follow-up study of a large international cohort of patients with KCNJ11 permanent neonatal diabetes, excellent glycemic control was maintained (HbA1c 8.1% before transfer to sulfonylureas, 5.9% at 1 year, and 6.4% at the last follow-up). 45 There were no reports of severe hypoglycemia in 809 patient-year follow up for the whole cohort and 93% of the participants remained on sulfonylurea therapy for the 10-year duration. As high as 14% of patients had reported mild, transient side effects which included diarrhea, nausea, weight loss due to reduced appetite, and abdominal pain. 44, 45 No patients discontinued SU treatment because of the side effects. Additional side effects were hepatitis steatosis and tooth discoloration. 45, 46, 51 As high as 9% patients had microvascular complications but these patients were noted to have been taking insulin longer than those without complications (20.5 years at time of transfer to SU therapy). 45 Pearson et al noted among 49 patients with diabetes due to KIR6.2 mutations, 90% of the patients successfully discontinued insulin after receiving sulfonylureas. 44 In another study of 14 patients with permanent neonatal diabetes mellitus due to KCNJ11 gene mutation (median age, 12.0 years; range, 5-50 years) who were transferred to SU therapy at least 2 prior, there was a 1.68% (range, 0.3-3.7%) initial reduction of HbA1c after the switch to SU (approximately 3-6 months post-transfer) and good glycemic control was maintained during the follow-up (median 34 months, range, 27-51 months) with average HbA1c level of 6.0% (range, 5.3-6.7%) at the last visit. 52 Only 1 patient had rapid progression of retinal changes. This patient was a 34-year-old female with preexisting proliferative diabetic retinopathy. 52 Younger age at initiation of SU therapy and shorter duration of diabetes are associated with higher rates of success in transition from insulin therapy to SU. 46, 53 Importantly, SU therapy can also lead to beneficial effects on neurocognitive development, especially with those who have KCNJ11 mutation. 2, [54] [55] [56] [57] The benefits appear to be most in patients in whom these drugs are started earlier. 54, 58 SU receptors are widely expressed in the brain and the improvement in neurological status suggests that SU drugs cross the blood-brain barrier in sufficient amount to close the neuronal K ATP channels. 56 Bowman et al in the 10-year multicenter follow-up study of KCNJ11 permanent neonatal diabetes reported improvement in CNS features in 47% of the patients that had CNS features at the time of transition to SU therapy. Improvements were noted in muscle tone, concentration or ADHD, gross motor skills, epilepsy, muscle weakness, learning difficulties, speech, and tics. However, this effect was usually incomplete and eventually plateaued. 45 Bertrand and colleagues also reported improved intelligence scores, hypotonia, visual attention deficits, and gross and fine motor skills after transitioning from insulin to SU therapy. 54 CNS features in KCNJ11 permanent neonatal diabetes persist despite longterm treatment with SU which is in contrast with the improved glycemic response. 45 The underlying reason for the poor CNS response may be the failure to achieve therapeutic concentration of these drugs in the CSF and brain of patients treated with oral SU to block K ATP channels enough to affect neuronal electrical activity. 59 The use of SU in pediatric patients is considered an off-label use. It is important to keep in mind that up to 10% of patients with KCNJ11 mutations causing neonatal DM will not respond to sulfonylurea and will require insulin lifelong. 53, 60 There can be a significant delay between clinical diagnosis of neonatal DM and genetic diagnosis of neonatal diabetes as was noted in the Monogenic Diabetes Registry (mean 10 weeks, range 1.6 to 58.2 weeks). 61 Given the potential beneficial effect on neurodevelopmental outcome and glycemic control, an empiric inpatient trial of SU therapy is suggested in the absence of consanguinity, syndromic features, and pancreatic hypoplasia/aplasia.
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Several approaches have been utilized for transition from insulin to SU. 2, 44, 50, [62] [63] [64] Patients can be on multiple daily insulin injections or on CSII prior to transition to SU. Point of care blood glucose should be checked before meals and at bedtime daily during the transition phase. 2, 44 Continuous glucose monitors can be helpful in monitoring blood glucose values in neonates. 65 The transition from insulin to SU can occur in an inpatient setting under the supervision of a physician with expertise in management of infants with diabetes. The transition may also be done as an outpatient provided the family and health providers are comfortable with adjustments in insulin and glyburide dosing based on blood glucose values during the transition phase. Pearson and colleagues recommend a blood glucose values cut off of 126 mg/dL for titrating the dose of glyburide. 44 The initial starting dose of glyburide is 0.1 mg/kg/dose twice daily before meals. Glyburide tablets can be crushed and administered as an aqueous suspension. In subsequent days, if the preprandial blood glucose at the time the dose of glyburide is due is greater than 126 mg/dL, the dose of glyburide can be increased by 0.1 mg/kg/dose. If pre-meal point of care glucose values continue to be above 126 mg/dL, dose should be increased to at least 1 mg/kg/day which is usually achieved in 5-7 days. Other experts recommend using a blood glucose cut off of 200 mg/dL to titrate the dose of glyburide due to the concern that the lower blood glucose threshold of 126 mg/dL places the child at a higher risk of hypoglycemia during the transition. 2 The dose of the long-acting insulin is decreased the night before giving glyburide or if the patient is using CSII, the basal insulin is decreased by 50% before breakfast on the day of giving the first dose of glyburide. Long-acting and intermediate-acting insulin analogs are discontinued on day 2 of the transition. Once glyburide has been started, the dose of the short-acting insulin dose is adjusted based on the preprandial blood glucose. For instance, if blood glucose is >200 mg/dL, the usual dose of short-acting insulin prior to the meal should be given. On the contrary, if blood glucose is <200 mg/dL, the preprandial dose of short-acting insulin should be reduced by at least 50%. 2 In most SU-responsive cases, insulin can be discontinued in 5-7 days. The slow outpatient transition begins with a starting glyburide dose of 0.1 mg per kilogram per day and increases by 0.1 mg per kilogram per day once a week. 44 The dose of glyburide is increased until insulin independence or until the dose was at least 0.8 mg per kilogram per day.
If the clinical response is unclear, measurement of glucose and C-peptide levels before and 90-120 mins after a meal when glyburide is being used can be helpful in assessing the effect of SU therapy in infants. Long-term treatment for neonatal DM requires the involvement of a multidisciplinary team. Blood glucose monitoring is recommended due to the risk of both hyperglycemia and hypoglycemia in children with neonatal diabetes. Hypoglycemia can be difficult to recognize in infants and toddlers and the only sign might be behavioral changes like irritability and inconsolable crying. Hypoglycemia can also be detrimental in regards to cognitive deficits. Infants with neonatal DM should be seen every 3 months. HbA1c should be assessed to measure average 3-month glycemic control but only if the patient is >6 months of age as it does not necessarily reflect average blood glucose values in infants <6 months of age due to higher level of HbF. Screening for microvascular and macrovascular complications of diabetes can be delayed until after the first 5 years after diagnosis since these are uncommon to develop in infants. 14 
Conclusion
Neonatal diabetes should be diagnosed in infants with persistent hyperglycemia and genetic testing should be considered at the onset in all patients with neonatal diabetes as knowledge of the presence of specific genetic mutations can significantly alter the treatment. Sulfonylurea treatment is the treatment of choice for patients with K ATP channel genetic mutation (KCNJ11 and ABCC8) and it has been shown to improve neurocognitive features. Close follow-up is recommended in all patients with neonatal diabetes due to their increased risk for both hyperglycemia and hypoglycemia.
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